2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Completed
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
1
Other hematologic neoplasm
1
Conditions
Neoplasms
1
Hematologic Neoplasms
1
Interventions
Cyclophosphamide
3155
Cisplatin
3151
Carboplatin
2929
Paclitaxel
2671
Radiotherapy
2643
Gemcitabine
2544
pembrolizumab
2324
Docetaxel
2154
Bevacizumab
2126
Fluorouracil
1819
Capecitabine
1780
Oxaliplatin
1709
Dexamethasone
1589
Nivolumab
1516
Doxorubicin
1477
Rituximab
1453
Etoposide
1341
Magnetic Resonance Spectroscopy
1261
Irinotecan
1232
Leucovorin
1212
Cytarabine
1123
Pemetrexed
1060
Drug Therapy
1060
fludarabine
1044
Vincristine
956
Specimen Handling
928
Prednisone
924
Cetuximab
919
Lenalidomide
916
Trastuzumab
897
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
kalinox
×
Clear all
NCT03755895
2025-10-03
HYCUDES
Institut de Cancérologie de Lorraine
Phase 2
Completed
68 enrolled
NCT03483194
2020-06-23
REVEH
Weprom
Phase 2/3
Completed
126 enrolled